IMV's Basket Clinical Study Shows Promising Top Line Data In Bladder Cancer

IMV Inc IMV announced the finalization of the basket clinical study evaluating maveropepimut-S (MVP-S) in combination with Merck & Co Inc's MRK Keytruda in patients with metastatic bladder and Micro-Satellite Instability High (MSI-H) solid tumors.

  • Clinical benefit (complete responses, partial responses, and stable disease) was observed in metastatic bladder cancer patients, including those who had received prior immune checkpoint inhibitor therapy.
  • Related: IMV's Shares Jump As Ovarian Cancer Candidate Shows Overall Survival Rate Of 44.9%
  • "The top-line clinical data from both the bladder and MSI-Hi cohorts are promising, further showcasing the potential of MVP-S as an immune-educating therapy in multiple cancer indications," said Jeremy Graff, Ph.D., Chief Scientific Officer at IMV. 
  • A complete set of data, including evaluation of PD-L1 and other measures, will be presented at an upcoming scientific conference.
  • Price Action: IMV shares are up 11.90% at $1.43 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralbladder cancerBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!